Positive results from a study of ivacaftor (Kalydeco®) in children ages 1 to 2 were announced today.
Site Search
Showing 1 - 10 of 24 results
Two Phase 3 clinical trials of tezacaftor (VX-661) in combination with ivacaftor (Kalydeco®) showed positive results, Vertex Pharmaceuticals announced today.
News
|
|
4 min read
News
|
|
1 min read
News
|
|
3 min read
News
|
|
2 min read
News
|
|
2 min read
News
|
|
1 min read
News
|
|
2 min read
A new inhaled antibiotic for the treatment of cystic fibrosis called Cayston® is now available for patients through select specialty pharmacies, including the CF Services Pharmacy.
News
|
|
2 min read
A key focus of this year's North American Cystic Fibrosis Conference (NACFC) was the progress of the more than 30 potential new therapies moving through the CF Foundation's drug development pipeline.
News
|
|
2 min read